心不全における貧血と鉄欠乏:現在の概念と新たな治療法
Inder S Anand1,2,3, Pankaj Gupta4,3
1VA Medical Center, Minneapolis, MN (I.A., P.G.) anand001@umn.edu.
Circulation
|July 4, 2018
まとめ
貧血と鉄欠乏症は,心不全の患者で一般的であり,結果に影響します. 静脈内鉄は症状と運動能力を改善しますが,長期的な安全性と有効性はさらなる研究が必要です.
科学分野:
- 心臓病科
- 血液学
背景:
- 貧血と鉄欠乏症は,心不全患者の共病である.
- これらの症状は,より悪い臨床状態と有害な結果と関連しています.
- 心不全の進行における貧血と鉄欠乏の正確な役割はまだ調査中です.
研究 の 目的:
- 心不全における貧血と鉄欠乏症の原因,病原性,治療方法を検討する.
- 心不全患者における鉄欠乏管理に関する現在の理解について議論する.
主な方法:
- 心不全における貧血と鉄欠乏に関する既存の文献のレビュー
- エリトロポエーシス刺激剤と静脈内鉄を含む治療戦略を評価した研究の分析
主要な成果:
- エリトポエーゼを刺激する薬は,心不全の患者で改善された結果を示せず,リスクも伴う.
- 静脈内鉄投与は小さな研究で症状と運動能力の改善に有望であることが示されましたが,長期的なデータは不足しています.
- 治療決定において,絶対的な鉄欠乏症と機能的な鉄欠乏症を区別することが重要です.
結論:
- 貧血と鉄欠乏症は,心不全の患者に著しく影響する.
- エリトロポエーシス刺激剤は推奨されないが,静脈内鉄は症状管理の可能性がある.
- 鉄補給の長期的な安全性と有効性を確立するには,さらなる研究が必要である.
関連する概念動画
Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Heart Failure II: Pathophysiology
975
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
975
Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction
924
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
924
Heart Failure Drugs: Diuretics
990
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
Heart Failure V: Medical Management
342
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342


